STAT3 Inhibitor Small Molecule Design for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STAT3 inhibitors face limitations in potency, specificity, and bioavailability, failing to effectively target and inhibit STAT3 activation in cancer cells, particularly in ER-negative breast cancers and other cancer types, due to issues with cellular permeability and pharmacokinetic profiles.
Innovation Solution
Development of synthetic low molecular-weight compounds that specifically block STAT3 activation, exhibiting improved potency, specificity, and drug-like properties such as water solubility and bioavailability, which can be used as potent orally active inhibitors for various cancers and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If peptide-based inhibitors are used to target STAT3, then binding affinity to STAT3 is improved, but cellular permeability deteriorates due to peptidic nature and negative charges
Solution Approach 1:
The patent transforms the chemical parameters of STAT3 inhibitors by transitioning from peptidic structures to non-peptidic small molecule structures. This fundamental parameter change in molecular architecture eliminates the inherent limitations of peptides (poor cellular permeability and metabolic instability) while maintaining the ability to bind STAT3 with high affinity through optimized molecular interactions in the ATP-binding pocket.
Solution Approach 2:
The patent replaces the peptidic chemical system with a small-molecule chemical system. This substitution fundamentally changes the physical and chemical properties of the inhibitor, enabling it to cross cell membranes effectively while maintaining target engagement through rational drug design that mimics the binding interactions of peptides without their detrimental properties.
2Ease of operation
If non-peptidic small-molecule inhibitors are used, then cellular permeability is improved, but binding affinity to STAT3 deteriorates
Solution Approach 1:
The patent optimizes molecular parameters of small-molecule inhibitors by carefully tuning structural features, substituent groups, and molecular geometry to achieve optimal fit within the STAT3 ATP-binding pocket. This parameter optimization enables non-peptidic compounds to attain high binding affinity (low nanomolar IC50 values) while maintaining the cellular permeability advantages of small molecules.
Solution Approach 2:
The patent creates small-molecule copies that replicate the essential binding interactions of peptide inhibitors with STAT3. By identifying key interaction motifs and recreating them with small-molecule chemistry, the invention achieves both high affinity binding and improved cellular permeability, effectively copying the functional advantages of peptides without their structural limitations.
3Reliability
If existing STAT3 inhibitors (e.g., niclosamide) are used, then STAT3 activation is inhibited, but pharmacokinetic properties deteriorate due to poor oral bioavailability and solubility
Solution Approach 1:
The patent systematically optimizes pharmacokinetic parameters of STAT3 inhibitors by modifying molecular properties such as lipophilicity, molecular weight, hydrogen bonding capacity, and solubility characteristics. These parameter changes enable the compounds to achieve both potent STAT3 inhibition and favorable oral bioavailability, addressing the pharmacokinetic limitations of earlier inhibitors like niclosamide.
Data Source
AI summary
Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.